ArticleTransplantation and cellular therapy2021

Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells.

Molly Mercedes Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.